Murine Glioblastoma Xenograft Model
Objective: In vivo assessment of TanCAR T cell efficacy in mitigating antigen escape, enhancing antitumor activity, and improving survival in a murine glioblastoma model
Protocol Steps
Murine Glioblastoma Model Establishment
Establish a murine glioblastoma xenograft model for in vivo assessment of TanCAR T cell efficacy
Note: This is a preclinical model used to test antigen escape mitigation and antitumor activity
View evidence from paper
“In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”
TanCAR T Cell Administration
Administer TanCAR T cells to tumor-bearing mice to assess therapeutic efficacy
Note: TanCAR T cells target both HER2 and IL13Rα2 antigens simultaneously
View evidence from paper
“TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2”
Assessment of Antigen Escape Mitigation
Monitor and measure the ability of TanCAR T cells to mitigate antigen escape variants during tumor progression
Note: Antigen escape variants can lead to tumor recurrence after CAR T cell treatment targeting single antigens
View evidence from paper
“In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells”
Measurement of Antitumor Activity
Evaluate enhanced antitumor efficacy of TanCAR T cells in the murine glioblastoma model
Note: TanCAR T cells exhibited enhanced antitumor activity compared to control treatments
View evidence from paper
“TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”
Survival Assessment
Monitor and record animal survival outcomes following TanCAR T cell treatment
Note: Survival improvement is a primary outcome measure in this in vivo model
View evidence from paper
“TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”